Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study

Inclusion Criteria: * Male or female patients, 18-45 yrs of age, in good general health * PRK candidate(Subjects willing and able to undergo bilateral PRK for the correction of their myopia. ) * Refractive error -1 to -8 diopters (spherical equivalent) at baseline * Females of childbearing age must have a negative pregnancy test result at baseline. A female considered to be of non-childbearing potential is she is postmenopausal (no menses for 12 consecutive months) or is without a uterus. * Ability to follow study instructions and likely to complete the entire course of the study(Subjects who are able to comply with all study procedures, including wearing a soft bandage contact lens in the immediate postoperative period. ) * Written informed consent will be obtained * Written HIPPA authorization will be obtained * Subjects with MRSE \<6.0 D, with less than 2.0 D of astigmatism. * Stable prescription in both eyes as defined by \<0.25 D change over the preceding 2 years. Exclusion Criteria: * Uncontrolled systemic disease you mean if someone has controlled DM or rheumatic disease can be included * Any active ocular disease, corneal abnormalities, lid abnormalities, or any ocular pathologies * History of serious eye disease, trauma, or previous ocular surgery * History of unstable myopia * History of herpes keratitis * Known allergy or hypersensitivity to the study medication * Anticipated wearing of contact lenses in addition to the required bandage contact lens post-PRK. Patients who wear soft contact lenses should discontinue wearing them at least 7 days prior to baseline visit. Patients wearing RGP or hard contact lenses should discontinue wearing them at least 3 weeks prior to baseline visit. * Females who are pregnant, breastfeeding, or trying to conceive. * Keratoconus or keratoconus suspect * Any condition or situation which, in the investigator's opinion, may put patient at significant risk or may confound the study results * Subjects who have a past or present disease, which as judged by the investigator may affect the safety of the subject or the outcome of the study. * Subjects who have previously had corneal surgery. * Subjects with any ocular disease or corneal abnormality, including but not limited to: * Decreased corneal sensation / neurotrophic cornea; * Corneal vascularization; * Keratoconus; * Keratoconjunctivitis sicca requiring chronic treatment; * Lagophthalmos; * Blepharitis; * History of infectious keratitis; * History of glaucoma or intraocular pressure of \>21 mmHg or use of glaucoma medications; * Significant dry eye disease that requires regular topical treatment; * Corneal thickness \<480 µm at the thinnest point, and * Posterior elevation \>40 micron. * Subjects who require any topical ophthalmic medication other than the pre- and postoperative regimen defined in the study protocol. * Subjects who are taking amiodarone, long acting anticholinergics, e.g., atropine, scopolamine, or medications or agents that can cause dry eye.